| Autor: |
Brainard DM; Merck & Co, Inc, 126 E. Lincoln Ave, P.O. Box 2000, Rahway, NJ 07065, USA. diana_brainard@merck.com, Kassahun K, Wenning LA, Petry AS, Liu C, Lunceford J, Hariparsad N, Eisenhandler R, Norcross A, DeNoia EP, Stone JA, Wagner JA, Iwamoto M |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical pharmacology [J Clin Pharmacol] 2011 Jun; Vol. 51 (6), pp. 943-50. Date of Electronic Publication: 2010 Sep 17. |
| DOI: |
10.1177/0091270010375959 |
| Abstrakt: |
Raltegravir is an HIV-1 integrase strand transfer inhibitor with potent activity against HIV-1. A prior investigation of raltegravir coadministered with rifampin demonstrated a decrease in plasma concentrations of raltegravir likely secondary to induction of UGT1A1, the enzyme primarily responsible for the metabolism of raltegravir. Little is known regarding the induction of UGT1A1 by rifabutin, an alternate rifamycin. In vitro characterization of the induction potency of rifampin and rifabutin on UGT1A1 was performed. In vitro studies indicate that rifabutin is a less potent inducer of UGT1A1 messenger RNA expression than is rifampin. A fixed-sequence, 2-period, clinical crossover study was conducted to assess the effect of rifabutin on plasma levels of raltegravir: period 1, 400 mg of raltegravir every 12 hours for 4 days; period 2, 400 mg of raltegravir every 12 hours and 300 mg of rifabutin once daily for 14 days. Geometric mean ratio (GMR) (coadministration of rifabutin and raltegravir vs raltegravir alone) of raltegravir area under the concentration-time curve from 0 to 12 hours post dose (AUC(0-12h)) and the 90% confidence interval (CI) was 1.19 (0.86-1.63); GMR of concentration at 12 hours (C(12h)) and 90% CI was 0.80 (0.68-0.94); and GMR of time to maximal concentration (C(max)) and 90% CI was 1.39 (0.87-2.21). Overall, coadministration of rifabutin did not alter raltegravir pharmacokinetics to a clinically meaningful degree. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text